These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37627268)

  • 21. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease.
    Sakai R; Suzuki M; Ueyama M; Takeuchi T; Minakawa EN; Hayakawa H; Baba K; Mochizuki H; Nagai Y
    PLoS One; 2019; 14(6):e0218261. PubMed ID: 31242217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minocycline inhibition of microglial rescues nigrostriatal dopaminergic neurodegeneration caused by mutant alpha-synuclein overexpression.
    Wang Y; Wang Q; Yu R; Zhang Q; Zhang Z; Li H; Ren C; Yang R; Niu H
    Aging (Albany NY); 2020 Jul; 12(14):14232-14243. PubMed ID: 32706757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
    PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau knockout exacerbates degeneration of parvalbumin-positive neurons in substantia nigra pars reticulata in Parkinson's disease-related α-synuclein A53T mice.
    Jiao L; Zheng M; Duan J; Wu T; Li Z; Liu L; Xiang X; Tang X; He J; Li X; Zhang G; Ding J; Cai H; Lin X
    FASEB J; 2020 Sep; 34(9):12239-12254. PubMed ID: 33000527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson's disease.
    García-Revilla J; Boza-Serrano A; Jin Y; Vadukul DM; Soldán-Hidalgo J; Camprubí-Ferrer L; García-Cruzado M; Martinsson I; Klementieva O; Ruiz R; Aprile FA; Deierborg T; Venero JL
    Acta Neuropathol; 2023 Jul; 146(1):51-75. PubMed ID: 37202527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.
    Diepenbroek M; Casadei N; Esmer H; Saido TC; Takano J; Kahle PJ; Nixon RA; Rao MV; Melki R; Pieri L; Helling S; Marcus K; Krueger R; Masliah E; Riess O; Nuber S
    Hum Mol Genet; 2014 Aug; 23(15):3975-89. PubMed ID: 24619358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.
    Liu CW; Giasson BI; Lewis KA; Lee VM; Demartino GN; Thomas PJ
    J Biol Chem; 2005 Jun; 280(24):22670-8. PubMed ID: 15840579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rab7 reduces α-synuclein toxicity in rats and primary neurons.
    Szegö EM; Van den Haute C; Höfs L; Baekelandt V; Van der Perren A; Falkenburger BH
    Exp Neurol; 2022 Jan; 347():113900. PubMed ID: 34695425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease.
    Koprich JB; Johnston TH; Reyes MG; Sun X; Brotchie JM
    Mol Neurodegener; 2010 Oct; 5():43. PubMed ID: 21029459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of α-Synuclein and Disease-Associated Factors in
    Suzuki M; Sango K; Nagai Y
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
    Gentzel RC; Toolan D; Jinn S; Schachter JB; Ma L; Kahle PJ; Smith SM; Marcus JN
    Neurobiol Aging; 2021 Oct; 106():12-25. PubMed ID: 34225000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.
    Sorrentino ZA; Hass E; Vijayaraghavan N; Gorion KM; Riffe CJ; Dhillon JS; Giasson BI
    Neurosci Lett; 2020 Jul; 732():135017. PubMed ID: 32371157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gangliosides, α-Synuclein, and Parkinson's Disease.
    Ledeen RW; Wu G
    Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
    Zhang LF; Yu XL; Ji M; Liu SY; Wu XL; Wang YJ; Liu RT
    Food Funct; 2018 Dec; 9(12):6414-6426. PubMed ID: 30462117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.